A diabetes drug developed by Sanofi-Aventis could significantly improve blood sugar level control, a Phase III study has found.
The company said that Lixisenatide, a once-daily treatment, helped patients with type 2 diabetes achieve HbA1c less than 7%.
The 12-week, GetGoal study of the drug, a GLP-1 agonist, involved 361 volunteers not currently receiving glucose-lowering therapy and with HbA1c between 7% and 10%.
Dr. Marc Cluzel, Sanofi’s executive vice-president for research and development, said: “We are pleased with the top-line results from our first Phase III study of this novel, once-daily GLP-1 agonist and are looking forward to sharing the full results later in the year.”
The complete findings will be presented at the 46th Annual Meeting of the European Association for the Study of Diabetes, to be held in Stockholm, in September 2010.
Copyright Press Association 2010